HCV Infection Clinical Trial
Official title:
Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents. Relationship With Clinical and Sociodemographic Variables
Study about the improvement of cognitive, psychopathological and functional abilities in Hepatitis C Virus (HCV) infected patients after eradication of the virus with direct antiviral agents.
The aim of this study is to investigate the effect that the eradication of the HCV has on
cognition, quality of life and psychopathology. At the same time, investigators intend to
study the association between cognitive changes and some clinical variables.
The sample consists of 80 subjects (40 HCV patients and 40 HCV patients coinfected with the
Human Immunodeficiency Virus, HIV). Exclusion criteria: Cirrhosis, presence of minimal
hepatic encephalopathy or active drug consumption.
A neuropsychological assessment is made before the treatment with direct antiviral agents to
evaluate memory, executive functions, processing speed, anxiety, depression and quality of
life. Additionally, the following clinical variables are collected: Viral charge,
immunosuppression (measured with T Cells CD4 (CD4), CD4 nadir and T Cells CD8 (CD8)) and
fibrosis level, HCV genotype and plasma biomarkers: Brain-Derived Neurotrophic Factor (BDNF),
Interleukine 6 (IL6), Tumor Necrosis Factor (TNF-a),Glial fibrillary acidic protein (GFAP),
Soluble CD14 (SCD14), Neuro-specific enolase (NSE).
The second neuropsychological assessment and clinical data collection is carried out after
treatment, concretely 6 months after HCV is undetectable in plasma.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03674125 -
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
|
Phase 1 | |
| Completed |
NCT00978497 -
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
| Completed |
NCT00170131 -
MMF Influence on HCV Viral Evolution After Liver Transplantation
|
Phase 4 | |
| Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
| Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
| Completed |
NCT01958281 -
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
|
Phase 2 | |
| Completed |
NCT02533427 -
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
|
Phase 1 | |
| Completed |
NCT02783976 -
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
|
||
| Withdrawn |
NCT04309734 -
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT01965535 -
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
|
Phase 2 | |
| Completed |
NCT00768690 -
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
|
Phase 1 | |
| Completed |
NCT00743795 -
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
| Withdrawn |
NCT04235049 -
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
|
Phase 4 | |
| Terminated |
NCT00401947 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
|
Phase 2 | |
| Completed |
NCT00959699 -
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
|
Phase 2 | |
| Completed |
NCT00623649 -
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
|
Phase 1 | |
| Completed |
NCT00221624 -
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
|
Phase 3 | |
| Completed |
NCT04134767 -
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
|
N/A | |
| Completed |
NCT02402452 -
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
|
Phase 1 | |
| Completed |
NCT00909636 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet
|
Phase 1 |